CSS
KROS icon

Cubist Systematic Strategies’s Keros Therapeutics KROS Stock Holding History

Cubist Systematic Strategies’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$1.92M Buy
+121,530
New +$1.8M 0.01% 1592
2025
Q2 		– Sell
-198,411
Closed -$2.02M – 3270
2025
Q1 		$2.02M Buy
198,411
+197,201
+16,298% +$2.29M 0.01% 1410
2024
Q4 		$19.2K Buy
+1,210
New +$62.9K ﹤0.01% 2843
2024
Q1 		– Sell
-411
Closed -$16.3K – 4021
2023
Q4 		$16.3K Buy
+411
New +$12.9K ﹤0.01% 3364
2023
Q2 		– Sell
-8,306
Closed -$355K – 3933
2023
Q1 		$355K Buy
8,306
+3,844
+86% +$194K ﹤0.01% 2876
2022
Q4 		$214K Buy
4,462
+4,167
+1,413% +$195K ﹤0.01% 3546
2022
Q3 		$11K Sell
295
-24,051
-99% -$834K ﹤0.01% 4282
2022
Q2 		$673K Buy
+24,346
New +$1.07M ﹤0.01% 2810
2022
Q1 		– Sell
-214
Closed -$13K – 3669
2021
Q4 		$13K Sell
214
-4,758
-96% -$237K ﹤0.01% 3392
2021
Q3 		$197K Buy
+4,972
New +$177K ﹤0.01% 2590
2021
Q2 		– Sell
-100
Closed -$6K – 3000
2021
Q1 		$6K Sell
100
-100
-50% -$6.34K ﹤0.01% 2787
2020
Q4 		$14K Sell
200
-707
-78% -$44.6K ﹤0.01% 2511
2020
Q3 		$35K Buy
907
+9
+1% +$357 ﹤0.01% 2385
2020
Q2 		$34K Buy
+898
New +$27.7K ﹤0.01% 2292

Other funds holding KROS

ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $295M AUM 40.98% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Cubist Systematic Strategies's KROS Position: Q3 2025 in Review

Cubist Systematic Strategies opened a new position in Keros Therapeutics (KROS) in Q3 2025: 121,530 shares worth $1.92M. The stake represents 0.01% of the portfolio and ranks #1592 among its holdings. This is a return to the name: Cubist Systematic Strategies previously reported a position in KROS as recently as Q1 2025.

Cubist Systematic Strategies first reported a position in KROS in Q2 2020 and has held it in 14 quarters since. The position peaked at $2.02M in Q1 2025. 155 funds tracked by Wall St. Rank hold KROS as of Q3 2025.

  • Cubist Systematic Strategies held 121,530 shares of Keros Therapeutics worth $1.92M as of Q3 2025.
  • Keros Therapeutics was a new Cubist Systematic Strategies position in Q3 2025.
  • Keros Therapeutics made up 0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #1592 holding.
  • Cubist Systematic Strategies first reported a position in Keros Therapeutics in Q2 2020 and has held it in 14 quarters since.
  • Cubist Systematic Strategies's Keros Therapeutics position peaked at $2.02M in Q1 2025.
  • 155 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.